Physician profile
John Owens
NPI 1538454871
$3,858.42
in general payments reported to CMS, 2019-2025
23 companies · $525 in 2025
The $525 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $449 · 2021: $764 · 2022: $567 · 2023: $338 · 2024: $235 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $909.49 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.66 | 2019-2023 | |
| Abbott Laboratories | $382.93 | 2020-2023 | Diamondback Coronary |
| Boston Scientific Corporation | $326.29 | 2019-2021 | |
| Pfizer INC. | $283.78 | 2019-2024 | |
| Amgen INC. | $269.07 | 2019-2023 | Repatha |
| Shockwave Medical, INC | $194.49 | 2025 | |
| Philips North America LLC | $168.56 | 2021-2024 | (Bq9) Coronary Ivus |
| Medtronic, INC. | $124.25 | 2021-2023 | Resolute Onyx |
| Medtronic Vascular, INC. | $114.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $84.29 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.96 | 2019-2023 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $64.46 | 2019 | |
| Lundbeck LLC | $60.44 | 2019-2021 | |
| Novo Nordisk INC | $53.96 | 2019-2024 | Ozempic, Rybelsus |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $41.05 | 2020-2022 | |
| Teleflex LLC | $37.55 | 2025 | Trapliner, Turnpike |
| Alnylam Pharmaceuticals INC. | $32.84 | 2023-2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $31.85 | 2019-2021 | |
| Livanova USA, INC. | $19.91 | 2020 | |
| Cardiovascular Systems INC. | $17.60 | 2022 | |
| Bridgebio Pharma, INC. | $13.97 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.